Search by Drug Name or NDC
NDC 00135-0096-26 Gaviscon 80; 14.2 mg/1; mg/1 Details
Gaviscon 80; 14.2 mg/1; mg/1
Gaviscon is a ORAL TABLET, CHEWABLE in the HUMAN OTC DRUG category. It is labeled and distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. The primary component is ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE.
Product Information
| NDC | 00135-0096 |
|---|---|
| Product ID | 0135-0096_1f37dcea-c641-435b-9d54-efa7f283481a |
| Associated GPIs | 48990002200504 |
| GCN Sequence Number | 065583 |
| GCN Sequence Number Description | mag/aluminum/sod bicarb/alginc TAB CHEW 14.2-80MG ORAL |
| HIC3 | D4B |
| HIC3 Description | ANTACIDS |
| GCN | 27589 |
| HICL Sequence Number | 001142 |
| HICL Sequence Number Description | MAGNESIUM TRISILICATE/ALUMINUM HYDROX/SOD BICARB/ALGINIC AC |
| Brand/Generic | Brand |
| Proprietary Name | Gaviscon |
| Proprietary Name Suffix | Regular Strength |
| Non-Proprietary Name | aluminum hydroxide and magnesium trisilicate |
| Product Type | HUMAN OTC DRUG |
| Dosage Form | TABLET, CHEWABLE |
| Route | ORAL |
| Active Ingredient Strength | 80; 14.2 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE |
| Labeler Name | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| Pharmaceutical Class | Calculi Dissolution Agent [EPC], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Small Intestine Fluid/Electrolyte Absorption [PE], Magnesium Ion Exchange Activity [MoA], Osmotic Activity |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA018685 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00135-0096-26 (00135009626)
| NDC Package Code | 0135-0096-26 |
|---|---|
| Billing NDC | 00135009626 |
| Package | 100 TABLET, CHEWABLE in 1 BOTTLE (0135-0096-26) |
| Marketing Start Date | 2011-06-13 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |